Epstein-barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil

Clinical Infectious Diseases

Volumn 56, Issue 2, 2013, Pages 248-254

  Loechelt, Brett J ^a   Boulware, David ^b   Green, Michael ^c   Baden, Lindsey R ^d   Gottlieb, Peter ^e   Krause Steinrauf, Heidi ^f   Weinberg, Adriana ^e  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

daclizumab; Epstein Barr virus; herpes viruses; mycophenolate mofetil; type 1 diabetes

Indexed keywords

DACLIZUMAB; DNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES VIRUS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROLOGY; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CYTOMEGALOVIRUS; DIABETES MELLITUS, TYPE 1; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84871779576     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis848     Document Type: Article

References (34)

1. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-608. (Pubitemid 41007846)
2. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-52.
3. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-8. (Pubitemid 34547482)
4. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010; 33:826-32.
5. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphopro-liferative disorder. New Engl J Med 2001; 345:1000.
6. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108:2874-80.
7. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39:327-46.
8. Buda K, Tubergen DG, Levin MJ. The frequency and consequences of varicella exposure and varicella infection in children receiving maintenance therapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1996; 18:106-12.
9. Eid AJ, Razonable RR. New developments in the management of cyto-megalovirus infection after solid organ transplantation. Drugs 2010; 70:965-81.
10. Furth SL, Sullivan EK, Neu AM, Tejani A, Fivush BA. Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1997; 1:37-42. (Pubitemid 127684806)
11. Gershon AA, Mervish N, LaRussa P, et al. Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis 1997; 176:1496-500. (Pubitemid 27518149)
12. Hamilton JK, Paquin LA, Sullivan JL, et al. X-linked lymphoprolifera-tive syndrome registry report. J Pediat 1980; 96:669-73. (Pubitemid 10110309)
13. Odumade OA, Hogquist KA, Balfour HH Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev 2011; 24:193-209.
14. Pinana JL, Martino R, Barba P, et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant 2010; 45:534-42.
15. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seroneg-ative Epstein-Barr virus status is the primary risk factor for posttrans-plantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14:214-21.
16. Wu JF, Ho MC, Ni YH, et al. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children. Transplantation 2009; 87:758-62.
17. Abderrahim E, Harzallah A, Barbouch S, et al. Lymphoproliferative disorders in kidney transplant recipients: incidence, clinical characteristics and outcome. Rev Med Interne 2008; 29:535-40.
18. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproli-ferative disorders. J Nephrol 1997; 10:136-45. (Pubitemid 27297130)
19. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94:2208-16. (Pubitemid 29467666)
20. Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998; 91:3079-83. (Pubitemid 28227562)
21. Libertiny G, Watson CJ, Gray DW, Welsh KI, Morris PJ. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001; 88:1330-4. (Pubitemid 32955411)
22. Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996; 10:248-55. (Pubitemid 26257940)
23. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lympho-proliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppres-sion. Transplantation 1996; 62:370-5. (Pubitemid 26277344)
24. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11:383-92.
25. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323:1723-8.
26. Kroll J, Li S, Levi M, Weinberg A. Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lym-phoproliferative disorder. J Clin Virol 2011; 52:231-5.
27. Abiko Y, Ikeda M, Hondo R. Secretion and dynamics of herpes simplex virus in tears and saliva of patients with Bell's palsy. Otol Neurotol 2002; 23:779-83.
28. Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med 1996; 124:27-30. (Pubitemid 26019621)
29. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protege study):1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487-97.
30. Hess RD. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J Clin Microbiol 2004; 42:3381-7. (Pubitemid 39045655)
31. Klutts JS, Ford BA, Perez NR, Gronowski AM. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J Clin Microbiol 2009; 47:3204-10.
32. Hourigan MJ, Doecke J, Mollee PN, et al. A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. Br J Haematol 2008; 141:904-7. (Pubitemid 351724876)
33. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010; 23:350-66.
34. Tanuseputro P, Zagorski B, Chan KJ, Kwong JC. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 2011; 29:8580-4.